Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DermTech, Inc.DMTK · Entity 89998 | Director | June 01, 2023 | June 05, 2023 |
| Natera, Inc.NTRA · Entity 2635 | Director | June 26, 2026 | July 01, 2026 |
| VIVUS INCVVUS · Entity 151460 | Director | February 20, 2020 | February 24, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DermTech, Inc.
Report date June 01, 2023 · Filed June 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 134,576 |
Reported balance
After 2023-06-01 transaction · row 1
1 source rowRow 1 · 2023-06-01 · Grant · Acquired 35,714 · Balance 134,576 F1: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service. The shares underlying any vested restricted stock units shall be released to the reporting person on June 1, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service. The shares underlying any vested restricted stock units shall be released to the reporting person on June 1, 2024.
Natera, Inc.
Report date June 26, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,927 |
Ending reported balance
After 2026-06-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-26 · Grant · Acquired 1,571 · Balance 5,821 F1: Represents the issuance of restricted stock units (RSUs) that shall vest in full on June 11, 2027. The RSUs will become fully vested in the event that the Issuer is subject to a change in control. F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Row 2 · 2026-06-26 · Grant · Acquired 106 · Balance 5,927 F3: Represents the issuance of RSUs to the Reporting Person in lieu of quarterly retainer fees of $23,750 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the issuance of restricted stock units (RSUs) that shall vest in full on June 11, 2027. The RSUs will become fully vested in the event that the Issuer is subject to a change in control.
F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3: Represents the issuance of RSUs to the Reporting Person in lieu of quarterly retainer fees of $23,750 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance.
VIVUS INC
Report date February 20, 2020 · Filed February 24, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.41 | Direct | 15,000 |
Reported balance
After 2020-02-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-20 · Grant · Acquired 15,000 · Balance 15,000 F1: One twelfth (1/12th) of the total number of shares underlying the option vest and become exercisable on the monthly anniversary date following June 5, 2019, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2018 Equity Incentive Plan) on the relevant vesting dates. F2: The option expires on the earlier of (a) February 20, 2027 and (b) the six (6) month anniversary of the date the reporting person ceases to be a Service Provider. |
Filing footnotes · ownership attribution and instrument terms
F1: One twelfth (1/12th) of the total number of shares underlying the option vest and become exercisable on the monthly anniversary date following June 5, 2019, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2018 Equity Incentive Plan) on the relevant vesting dates.
F2: The option expires on the earlier of (a) February 20, 2027 and (b) the six (6) month anniversary of the date the reporting person ceases to be a Service Provider.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Oxford Immunotec Global PLC
Report date March 08, 2021 · Filed March 12, 2021
Section 16 reporting ended · disclosed 2021-03-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 1
1 source rowRow 1 · 2021-03-08 · Disposition to issuer · Disposed 4,081 · Balance 0 F1: Disposed pursuant to the acquisition by PerkinElmer (UK) Holdings Limited of the entire issued share capital of Oxford Immunotec Global PLC on March 8, 2021 by means of a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.65 · Expires 2026-06-28 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.46 · Expires 2027-06-06 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.49 · Expires 2028-06-19 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.44 · Expires 2029-06-18 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.40 · Expires 2023-11-22 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.40 · Expires 2023-11-22 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-03-08 · Disposition to issuer · Disposed 14,914 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.86 · Expires 2024-06-12 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.17 · Expires 2025-06-09 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.96 · Expires 2030-06-24 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-03-08 · Disposition to issuer · Disposed 9,494 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed pursuant to the acquisition by PerkinElmer (UK) Holdings Limited of the entire issued share capital of Oxford Immunotec Global PLC on March 8, 2021 by means of a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme").
F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price.
F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 08, 2021 Filed Nov 10, 2021 02:30 UTC Amendment | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionCommon Stock | 44,503 | $2.66 | $118,240.02 |
DisclosureSEC source: 0001415889-21-005123 · form4a-11092021_061106.xml · nonDerivative · entry 1 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,778 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2021 Filed Nov 9, 2021 20:25 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionStock Option (right to buy) · Derivative | 44,503 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0001415889-21-005106 · form4-11092021_121122.xml · derivative · entry 6 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,901 Underlying: Common Stock · 44,503 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option shares are fully vested and may be exercised at any time. Read SEC document |
| November 08, 2021 Filed Nov 9, 2021 20:25 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 400 | $120.24 | $48,096.00 |
DisclosureSEC source: 0001415889-21-005106 · form4-11092021_121122.xml · nonDerivative · entry 5 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,275 F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.19 to $120.31 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 08, 2021 Filed Nov 9, 2021 20:25 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 2,832 | $119.62 | $338,758.18 |
DisclosureSEC source: 0001415889-21-005106 · form4-11092021_121122.xml · nonDerivative · entry 4 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,675 F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.16 to $120.11 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 08, 2021 Filed Nov 9, 2021 20:25 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 2,100 | $118.79 | $249,454.80 |
DisclosureSEC source: 0001415889-21-005106 · form4-11092021_121122.xml · nonDerivative · entry 3 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,507 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.12 to $119.0250 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 08, 2021 Filed Nov 9, 2021 20:25 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 39,171 | $17.13 | $670,893.47 |
DisclosureSEC source: 0001415889-21-005106 · form4-11092021_121122.xml · nonDerivative · entry 2 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,607 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.00 to $117.92 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 08, 2021 Filed Nov 9, 2021 20:25 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionCommon Stock | 44,503 | $2.66 | $118,240.02 |
DisclosureSEC source: 0001415889-21-005106 · form4-11092021_121122.xml · nonDerivative · entry 1 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,778 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2021 Filed Jun 3, 2021 00:06 UTC | Natera, Inc. NTRA · Entity 2635 | GrantStock Option (right to buy) · Derivative | 2,614 | $0.00 Strike: $94.14 | $0.00 |
DisclosureSEC source: 0001415889-21-002774 · form4-06022021_050625.xml · derivative · entry 4 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,614 Underlying: Common Stock · 2,614 shares Expires 2031-05-27 F4 · derivative.exercise_date: The option shares shall vest and become exercisable in full on May 25, 2022. The option shares will become fully vested and exercisable in the event that the Issuer is subject to a change in control. Read SEC document |
| May 28, 2021 Filed Jun 3, 2021 00:06 UTC | Natera, Inc. NTRA · Entity 2635 | GrantRestricted Stock Unit · Derivative | 1,307 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-002774 · form4-06022021_050625.xml · derivative · entry 3 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,307 Underlying: Common Stock · 1,307 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSU shall vest in full on May 25, 2022. The RSU will become fully vested in the event that the Issuer is subject to a change in control. F3 · derivative.expiration_date: The RSU shall vest in full on May 25, 2022. The RSU will become fully vested in the event that the Issuer is subject to a change in control. Read SEC document |
| May 28, 2021 Filed Jun 3, 2021 00:06 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionRestricted Stock Unit · Derivative | 2,856 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-002774 · form4-06022021_050625.xml · derivative · entry 2 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,856 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSU vested in full on May 28, 2021. F2 · derivative.expiration_date: The RSU vested in full on May 28, 2021. Read SEC document |
| May 28, 2021 Filed Jun 3, 2021 00:06 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionCommon Stock | 2,856 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-21-002774 · form4-06022021_050625.xml · nonDerivative · entry 1 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 26, 2021 Filed May 29, 2021 00:21 UTC | DermTech, Inc. DMTK · Entity 89998 | GrantCommon Stock | 4,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-036713 · doc4.xml · nonDerivative · entry 2 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,382 F2 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest, and the shares underlying the restricted stock units shall be released to the reporting person, on January 1, 2023, subject to the reporting person's continued service. Read SEC document |
| May 26, 2021 Filed May 29, 2021 00:21 UTC | DermTech, Inc. DMTK · Entity 89998 | GrantCommon Stock | 4,497 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-036713 · doc4.xml · nonDerivative · entry 1 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,721 F1 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service. The shares underlying any vested restricted stock units shall be released to the reporting person on May 26, 2022. Read SEC document |
| March 08, 2021 Filed Mar 12, 2021 21:37 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Disposition to issuerStock Option (Right to Buy) · Derivative | 9,494 | $9.04 Strike: $12.96 | $85,825.76 |
DisclosureSEC source: 0001140361-21-008353 · form4.xml · derivative · entry 10 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,494 shares Expires 2030-06-24 F3 · price: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2 · derivative.exercise_date: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. Read SEC document |
| March 08, 2021 Filed Mar 12, 2021 21:37 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,457 | $7.83 Strike: $14.17 | $58,388.31 |
DisclosureSEC source: 0001140361-21-008353 · form4.xml · derivative · entry 9 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,457 shares Expires 2025-06-09 F3 · price: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2 · derivative.exercise_date: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. Read SEC document |
| March 08, 2021 Filed Mar 12, 2021 21:37 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,457 | $5.14 Strike: $16.86 | $38,328.98 |
DisclosureSEC source: 0001140361-21-008353 · form4.xml · derivative · entry 8 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,457 shares Expires 2024-06-12 F3 · price: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2 · derivative.exercise_date: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. Read SEC document |
| March 08, 2021 Filed Mar 12, 2021 21:37 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Disposition to issuerStock Option (Right to Buy) · Derivative | 14,914 | $6.60 Strike: $15.40 | $98,432.40 |
DisclosureSEC source: 0001140361-21-008353 · form4.xml · derivative · entry 7 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 14,914 shares Expires 2023-11-22 F3 · price: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2 · derivative.exercise_date: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. Read SEC document |
| March 08, 2021 Filed Mar 12, 2021 21:37 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,457 | $6.60 Strike: $15.40 | $49,216.20 |
DisclosureSEC source: 0001140361-21-008353 · form4.xml · derivative · entry 6 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,457 shares Expires 2023-11-22 F3 · price: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2 · derivative.exercise_date: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. Read SEC document |
| March 08, 2021 Filed Mar 12, 2021 21:37 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,457 | $7.56 Strike: $14.44 | $56,374.92 |
DisclosureSEC source: 0001140361-21-008353 · form4.xml · derivative · entry 5 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,457 shares Expires 2029-06-18 F3 · price: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2 · derivative.exercise_date: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. Read SEC document |
| March 08, 2021 Filed Mar 12, 2021 21:37 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,457 | $7.51 Strike: $14.49 | $56,002.07 |
DisclosureSEC source: 0001140361-21-008353 · form4.xml · derivative · entry 4 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,457 shares Expires 2028-06-19 F3 · price: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2 · derivative.exercise_date: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. Read SEC document |
| March 08, 2021 Filed Mar 12, 2021 21:37 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,457 | $7.54 Strike: $14.46 | $56,225.78 |
DisclosureSEC source: 0001140361-21-008353 · form4.xml · derivative · entry 3 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,457 shares Expires 2027-06-06 F3 · price: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2 · derivative.exercise_date: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. Read SEC document |
| March 08, 2021 Filed Mar 12, 2021 21:37 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,457 | $13.35 Strike: $8.65 | $99,550.95 |
DisclosureSEC source: 0001140361-21-008353 · form4.xml · derivative · entry 2 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,457 shares Expires 2026-06-28 F3 · price: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2 · derivative.exercise_date: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. Read SEC document |
| March 08, 2021 Filed Mar 12, 2021 21:37 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Disposition to issuerOrdinary Shares | 4,081 | $22.00 | $89,782.00 |
DisclosureSEC source: 0001140361-21-008353 · form4.xml · nonDerivative · entry 1 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed pursuant to the acquisition by PerkinElmer (UK) Holdings Limited of the entire issued share capital of Oxford Immunotec Global PLC on March 8, 2021 by means of a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme"). Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:04 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | GrantShare Option (Right to Buy) · Derivative | 9,494 | $0.00 Strike: $12.96 | $0.00 |
DisclosureSEC source: 0001437749-20-013984 · rdgdoc.xml · derivative · entry 2 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,494 Underlying: Ordinary Shares · 9,494 shares Expires 2030-06-24 F1 · security: Options granted under Issuer's 2013 Share Incentive Plan. F2 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the underlying shares on the earlier of the first anniversary of the date of grant or the date of the first annual general meeting of the shareholders held after the date of grant. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:04 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | GrantOrdinary Shares | 4,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-013984 · rdgdoc.xml · nonDerivative · entry 1 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,081 Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:21 UTC | DermTech, Inc. DMTK · Entity 89998 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037924 · doc4.xml · nonDerivative · entry 1 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,224 F1 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. All of the restricted stock units shall vest in a single installment on June 17, 2021, subject to the reporting person's continued service through the earlier to occur of (i) June 17, 2021 or (ii) the date of the issuer's 2021 Annual Meeting of Stockholders. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 22:45 UTC | Natera, Inc. NTRA · Entity 2635 | GrantStock Option (right to buy) · Derivative | 5,712 | $0.00 Strike: $40.93 | $0.00 |
DisclosureSEC source: 0001179110-20-007467 · edgar.xml · derivative · entry 2 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,712 Underlying: Common Stock · 5,712 shares Expires 2030-06-11 F3 · derivative.exercise_date: The option shares shall vest and become exercisable in full on May 28, 2021. The option shares will become fully vested and exercisable in the event that the Issuer is subject to a change in control. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 22:45 UTC | Natera, Inc. NTRA · Entity 2635 | GrantRestricted Stock Units · Derivative | 2,856 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-007467 · edgar.xml · derivative · entry 1 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,856 Underlying: Common Stock · 2,856 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The RSU shall vest in full on May 28, 2021. The RSU will become fully vested in the event that the Issuer is subject to a change in control. F2 · derivative.expiration_date: The RSU shall vest in full on May 28, 2021. The RSU will become fully vested in the event that the Issuer is subject to a change in control. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 18:07 UTC | VIVUS INC VVUS · Entity 151460 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.41 | $0.00 |
DisclosureSEC source: 0001123292-20-000327 · edgar.xml · derivative · entry 1 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F1 · derivative.exercise_date: One twelfth (1/12th) of the total number of shares underlying the option vest and become exercisable on the monthly anniversary date following June 5, 2019, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2018 Equity Incentive Plan) on the relevant vesting dates. F2 · derivative.expiration_date: The option expires on the earlier of (a) February 20, 2027 and (b) the six (6) month anniversary of the date the reporting person ceases to be a Service Provider. Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 21:16 UTC | DermTech, Inc. DMTK · Entity 89998 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-006001 · doc4.xml · nonDerivative · entry 1 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,224 F1 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's Amended and Restated 2010 Stock Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. Subject to the reporting person's continued service, all of the restricted stock units shall vest in a single installment on the date of the 2020 annual meeting of the stockholders of the issuer. Read SEC document |
| December 31, 2019 Filed Jan 4, 2020 00:52 UTC | DermTech, Inc. DMTK · Entity 89998 | Exercise / conversionRestricted Stock Units · Derivative | 17,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-001417 · doc4.xml · derivative · entry 2 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,703 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The shares of Issuer common stock underlying these restricted stock units have fully vested and were released to the reporting person on December 31, 2019. F2 · derivative.expiration_date: The shares of Issuer common stock underlying these restricted stock units have fully vested and were released to the reporting person on December 31, 2019. Read SEC document |
| December 31, 2019 Filed Jan 4, 2020 00:52 UTC | DermTech, Inc. DMTK · Entity 89998 | Exercise / conversionCommon Stock | 17,703 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-001417 · doc4.xml · nonDerivative · entry 1 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 18, 2019 Filed Jun 19, 2019 20:30 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | GrantSHARE OPTION (RIGHT TO BUY) · Derivative | 7,457 | $0.00 Strike: $14.44 | $0.00 |
DisclosureSEC source: 0001437749-19-012286 · rdgdoc.xml · derivative · entry 1 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,457 Underlying: ORDINARY SHARES · 7,457 shares Expires 2029-06-18 F1 · derivative.exercise_date: The option will vest and become exercisable as to 100% of the underlying shares on the date of the first annual meeting of the issuer's shareholders held after the date of grant. Read SEC document |
| May 24, 2019 Filed May 29, 2019 22:07 UTC | Natera, Inc. NTRA · Entity 2635 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $22.83 | $0.00 |
DisclosureSEC source: 0001179110-19-006810 · edgar.xml · derivative · entry 1 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-05-23 F1 · derivative.exercise_date: The option shares will vest and become exercisable in full on the earlier of (x) the date that is 12 months following the date of grant (May 24, 2019) or (y) the date of the annual stockholder meeting next following the grant. The option shares will become fully vested and exercisable in the event that the Company is subject to a change in control. Read SEC document |
| May 16, 2019 Filed Dec 3, 2019 22:47 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionRestricted Stock Unit · Derivative | 7,278 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-012277 · edgar.xml · derivative · entry 2 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,278 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the common stock of the issuer. F3 · derivative.exercise_date: The RSUs vested in full as of the date of the annual stockholder meeting, May 16, 2019. F3 · derivative.expiration_date: The RSUs vested in full as of the date of the annual stockholder meeting, May 16, 2019. Read SEC document |
| May 16, 2019 Filed Dec 3, 2019 22:47 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionCommon Stock | 7,278 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-19-012277 · edgar.xml · nonDerivative · entry 1 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the full vesting and settlement of Restricted Stock Units ("RSUs"), on May 16, 2019. F2 · price: Each RSU represents a contingent right to receive one share of the common stock of the issuer. Read SEC document |
| April 12, 2019 Filed Apr 17, 2019 01:26 UTC | Natera, Inc. NTRA · Entity 2635 | GrantRestricted Stock Units · Derivative | 7,278 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005048 · edgar.xml · derivative · entry 1 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,278 Underlying: Common Stock · 7,278 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Common Stock of the Issuer. F2 · derivative.exercise_date: The RSUs will vest and become exercisable in full on the earlier of (x) the date that is 12 months following the date of grant (April 12, 2019) or (y) the date of the annual stockholder meeting next following the grant. The RSU shares will become fully vested and exercisable in the event that the Company is subject to a change in control. F2 · derivative.expiration_date: The RSUs will vest and become exercisable in full on the earlier of (x) the date that is 12 months following the date of grant (April 12, 2019) or (y) the date of the annual stockholder meeting next following the grant. The RSU shares will become fully vested and exercisable in the event that the Company is subject to a change in control. Read SEC document |
| October 26, 2018 Filed Oct 29, 2018 19:54 UTC | VIVUS INC VVUS · Entity 151460 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001123292-18-001044 · edgar.xml · derivative · entry 3 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F2 · derivative.exercise_date: One twelfth (1/12th) of the total number of shares underlying the option vest and become exercisable on the 26th of each month following October 26, 2018, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2018 Equity Incentive Plan) on the relevant vesting dates. F3 · derivative.expiration_date: The option expires on the earlier of (a) October 26, 2025 and (b) the six (6) month anniversary of the date the reporting person ceases to be a Service Provider. Read SEC document |
| September 14, 2018 Filed Sep 18, 2018 22:37 UTC | Natera, Inc. NTRA · Entity 2635 | GrantRestricted Stock Units · Derivative | 5,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-011535 · edgar.xml · derivative · entry 2 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,785 Underlying: Common Stock · 5,785 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Common Stock of the Issuer. F3 · derivative.exercise_date: The RSUs will vest and become exercisable in full on the earlier of (x) the date that is 12 months following the date of grant (September 14, 2018) or (y) the date of the annual stockholder meeting next following the grant. The RSU shares will become fully vested and exercisable in the event that the Company is subject to a change in control. F3 · derivative.expiration_date: The RSUs will vest and become exercisable in full on the earlier of (x) the date that is 12 months following the date of grant (September 14, 2018) or (y) the date of the annual stockholder meeting next following the grant. The RSU shares will become fully vested and exercisable in the event that the Company is subject to a change in control. Read SEC document |
| September 14, 2018 Filed Sep 18, 2018 22:37 UTC | Natera, Inc. NTRA · Entity 2635 | GrantStock Option (right to buy) · Derivative | 11,169 | $0.00 Strike: $24.42 | $0.00 |
DisclosureSEC source: 0001179110-18-011535 · edgar.xml · derivative · entry 1 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,169 Underlying: Common Stock · 11,169 shares Expires 2028-09-13 F1 · derivative.exercise_date: The option shares will vest and become exercisable in full on the earlier of (x) the date that is 12 months following the date of grant (September 14, 2018) or (y) the date of the annual stockholder meeting next following the grant. The option shares will become fully vested and exercisable in the event that the Company is subject to a change in control. Read SEC document |
| September 14, 2018 Filed Apr 17, 2019 01:24 UTC Amendment | Natera, Inc. NTRA · Entity 2635 | GrantRestricted Stock Units · Derivative | 5,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005044 · edgar.xml · derivative · entry 1 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,785 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Common Stock of the Issuer. F2 · derivative.exercise_date: The RSUs will vest and become exercisable in full on the earlier of (x) the date that is 12 months following the date of grant (September 14, 2018) or (y) the date of the annual stockholder meeting next following the grant. The RSU shares will become fully vested and exercisable in the event that the Company is subject to a change in control. F2 · derivative.expiration_date: The RSUs will vest and become exercisable in full on the earlier of (x) the date that is 12 months following the date of grant (September 14, 2018) or (y) the date of the annual stockholder meeting next following the grant. The RSU shares will become fully vested and exercisable in the event that the Company is subject to a change in control. F3 · balance_after: The grant of Restricted Stock Units on September 14, 2018 were not granted on September 14, 2018 and was reported in error. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 16:10 UTC | VIVUS INC VVUS · Entity 151460 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001123292-18-000848 · edgar.xml · derivative · entry 3 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 25,000 shares Expires 2024-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One-twelfth (1/12th) of the total number of shares subject to the option shall vest and become exercisable on the 27th of each month following October 27, 2017, subject to such individual continuing to be a Service Provider (as defined in the 2010 Equity Incentive Plan) on the relevant vesting dates. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 16:10 UTC | VIVUS INC VVUS · Entity 151460 | Exercise / conversionCommon Stock | 25,000 | $0.70 | $17,500.00 |
DisclosureSEC source: 0001123292-18-000848 · edgar.xml · nonDerivative · entry 1 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 20:31 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | GrantSHARE OPTION (RIGHT TO BUY) · Derivative | 7,457 | $0.00 Strike: $14.49 | $0.00 |
DisclosureSEC source: 0001437749-18-012236 · rdgdoc.xml · derivative · entry 1 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,457 Underlying: ORDINARY SHARES · 7,457 shares Expires 2028-06-19 F1 · derivative.exercise_date: The option will vest and become exercisable as to 100% of the underlying shares on the date of the first annual meeting of the issuer's shareholders held after the date of grant. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 21:31 UTC | VIVUS INC VVUS · Entity 151460 | PurchaseCommon Stock | 50,000 | $0.77 | $38,500.00 |
DisclosureSEC source: 0001123292-18-000798 · edgar.xml · nonDerivative · entry 1 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Shares purchased by wife Disclosed balance after: 50,000 F1 · price: The weighted average price is $0.7688 and has been rounded to the next whole number. Shares were purchased in multiple transactions at prices from $0.76 to $0.7691. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| May 29, 2018 Filed May 31, 2018 16:33 UTC | VIVUS INC VVUS · Entity 151460 | PurchaseCommon Stock | 50,000 | $0.79 | $39,500.00 |
DisclosureSEC source: 0001123292-18-000764 · edgar.xml · nonDerivative · entry 1 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,671 F1 · price: This is the weighted average purchase price. Shares were purchased in multiple transactions at prices from $0.7727 to $0.79. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| May 21, 2018 Filed May 23, 2018 17:05 UTC | VIVUS INC VVUS · Entity 151460 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001123292-18-000756 · edgar.xml · derivative · entry 3 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2024-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One twelfth (1/12th) of the total number of shares subject to the option shall vest and become exercisable on the 27th of each month following October 27, 2017, subject to such individual continuing to be a Service Provider (as defined in the 2010 Equity Incentive Plan) on the relevant vesting dates. Read SEC document |
| May 21, 2018 Filed May 23, 2018 17:05 UTC | VIVUS INC VVUS · Entity 151460 | PurchaseCommon Stock | 100,000 | $0.81 | $81,000.00 |
DisclosureSEC source: 0001123292-18-000756 · edgar.xml · nonDerivative · entry 2 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,671 F1 · price: The price reported in Column 4 is the weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.7839 to $0.8248, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 21, 2018 Filed May 23, 2018 17:05 UTC | VIVUS INC VVUS · Entity 151460 | Exercise / conversionCommon Stock | 75,000 | $0.70 | $52,500.00 |
DisclosureSEC source: 0001123292-18-000756 · edgar.xml · nonDerivative · entry 1 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 27, 2017 Filed Oct 31, 2017 17:48 UTC | VIVUS INC VVUS · Entity 151460 | Exercise / conversionRestricted Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-17-001649 · edgar.xml · derivative · entry 4 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units converted into VIVUS, Inc. common stock on a 1-for-1 basis. F4 · derivative.exercise_date: The restricted stock units (RSUs) vest according to the following schedule: Commencing on November 8, 2016, 1/4th of the total RSUs originally granted shall vest on each of February 8, 2017, May 8, 2017, August 8, 2017 and November 8, 2017; provided, however, that (a) if the next annual stockholder meeting occurs prior to November 8, 2017 and the individual has remained a Service Provider (as defined in the VIVUS, Inc. 2010 Equity Incentive Plan), the vesting of the RSUs shall accelerate in full as of the date of the next annual stockholder meeting and (b) if the individual ceases to be a Service Provider (other than removal for cause) prior to any of the foregoing vesting dates, then 1/12th of the shares underlying the RSUs shall accelerate for each month elapsed from the most recent vesting date until the month in which the individual (i) ceases to be a Service Provider and (ii) has remained a Service Provider through at least the 8th day of such month. F4 · derivative.expiration_date: The restricted stock units (RSUs) vest according to the following schedule: Commencing on November 8, 2016, 1/4th of the total RSUs originally granted shall vest on each of February 8, 2017, May 8, 2017, August 8, 2017 and November 8, 2017; provided, however, that (a) if the next annual stockholder meeting occurs prior to November 8, 2017 and the individual has remained a Service Provider (as defined in the VIVUS, Inc. 2010 Equity Incentive Plan), the vesting of the RSUs shall accelerate in full as of the date of the next annual stockholder meeting and (b) if the individual ceases to be a Service Provider (other than removal for cause) prior to any of the foregoing vesting dates, then 1/12th of the shares underlying the RSUs shall accelerate for each month elapsed from the most recent vesting date until the month in which the individual (i) ceases to be a Service Provider and (ii) has remained a Service Provider through at least the 8th day of such month. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.